#Myelogenous Leukemia Opportunities US

[pharmanucleus1]

Global Leukemia Therapeutics Market, Forecast 2027

Leukemia Therapeutics Market

Leukemia is a type of blood cancer caused by gene mutation leading to abnormal development of WBCs in the bone marrow and causes leukemia. Leukemia is also caused due to risk factors such as genetic disorders such as Down syndrome, previous cancer treatments, exposure to chemicals, smoking, and family history of leukemia or other blood disorders. The major types of leukemia are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL). The majority of the AML, CML & CLL cases could be observed in adult populations, and ALL could be seen in all age groups. Leukemia treatment is based on its type, age, and ability to cope-up with the treatments. 

Market Size & Growth Rate: 

The leukemia therapeutics market was valued at USD 13.5 billion in 2021 and is projected to reach USD 17.1 billion by 2027, with a CAGR of 7.2% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies. 

Click here for full report:

https://www.pharmanucleus.com/reports/leukemia-therapeutics-market

Market Dynamics: 

On account of the growing number of people suffering from leukemia, the leukemia therapeutics treatment market has been driven by technological research & developments, the merging of healthcare organizations and new approvals in the field of blood cancer diagnostics across the globe. 

The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP)-April 2021, announced five new investments in increasing the development of new and improved immunotherapies in Abintus Bio, Nexlmmune, Caribou Biosciences and Immune-Onc Therapeutics for the treatment of leukemia cancer. 

Moreover, raising public awareness about the benefits of preventive healthcare is likely to move the demand for leukemia therapeutics treatment forward throughout the forecast period. Additionally, the Government initiatives and programs at increasing cancer awareness are expected to drive leukemia therapeutics treatment market expansion until 2027. 

Market Drivers: 

The growing research and technological development activities. 

Increasing product approval and product launch by the market players are expected to propel the leukemia therapeutics market, and also technological developments are likely to create various new opportunities that will impact this leukemia therapeutics market growth in the forecast period. For instance, 

In May 2022, Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) received FDA approval for combination with azacitidine in newly diagnosed AML with a susceptible IDH1 mutation in adults 75 years and older. 

On June 2021, Jazz Pharmaceuticals received FDA approval for a new form of Rylaze (asparaginase erwinia chrysanthemi recombinant rywn) to be developed as part of a treatment for children and adults with ALL 

In October 2021, Kite Pharma received FDA approval for use of the CAR T-cell therapy brexucabtagene autoleucel developed by Tecartus (the first CAR T-cell therapy approved) in adults with B-cell precursor ALL 

In November 2018, Pfizer Inc. received U.S. FDA approval for Glasdegib (DAURISMO), the Hedgehog pathway inhibitor for the treatment of adults suffering from AML 

Increasing incidence of leukemia to boost leukemia therapeutics market growth. 

One of the foremost driving factors influencing the global market is the increasing prevalence of leukemia across the globe, according to the National Cancer Institute (NCI), approximately 1.5% of people were diagnosed with leukemia during their lifetime. Additionally, in the report-2022, the estimated number of living people with new leukemia cases will be 60,650, and the number of death cases will be 24,000 in the United States. 

According to the American Cancer Society-2022, the CLL segment is anticipated 20,160 diagnosis cases including both children & adults in US leukemia therapeutic market, as CLL is the first line of treatment for it followed by AML and CML. 

Click here for full report:

Get more details on this report - Request Free Sample

Substantial progress has been made against cancer in recent decades. As of 2019, the rate has declined by 32%, mostly because of advances in early detection and treatment for some cancers including leukemia. It reflects largely driven by progress against leukemia cancer. 

Challenges: 

The high cost of treatment and stringent regulatory scenario restrain the market growth. 

High cost of treatment and stringent regulatory scenario restraint the market growth over the forecast period. For instance, the NCI-2022 report estimates that cancer-related direct medical costs in the US were USD 183 billion in 2015 and are projected to increase to USD 246 billion by 2030, a 34% increase based only on population growth and aging. 

The low diagnosis rate of leukemia & lack of proper healthcare facilities in developing countries 

Adverse reactions of leukemia therapeutics 

Competitive landscape:                                                                                                                     

Novartis International AG, Bristol Myers Squibb, Sanofi S.A, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical, Celgene Corporation, GlaxoSmithKline plc, Abintus Bio, Nexlmmune, Exelixis Inc., MorphoSys AG, Otsuka Holdings Company Ltd, AbbVie, Ambit Biosciences corporation, Ariad Pharmaceuticals, Gennzme Corporation, Rpche,  and Others. 

Key Developments: 

Get more details on this report - Request Free Sample

Regional Analysis: 

North America was the largest region in the leukemia therapeutics market in recent years and it is anticipated to capture the highest share of this market over the forecast period 2022-2027, with the U.S. accounting for the maximum contribution and it has well-developed structural healthcare systems. In addition, the high prevalence of leukemia and the rising geriatric population, based on the NCI-2022 report, leukemia represents 3.2% of all new cancer cases in the U.S., and the incidence rate increased in children and adolescents by about 1% per year and was stable in adults ages 20 and older. The presence significant of key players, some of the best research universities, and encouraging new product developments & launches for research lead to more significant assets in the pipeline. For instance, 

In October 2022, The American Cancer Society (ACS) approved funding for 89 new Extramural Discovery Science (EDS) research grants totaling USD 54.3 million. It will fund investigators at 65 institutions across the United States from January 1, 2023.?                                                                                                       

In November 2021, Pfizer Company acquired Trillium Therapeutics for approximately USD 2.22 billion, to enhance its oncology portfolio with the addition of next-generation immune therapies. 

[sweetmoxiety]

Behind This Mask Is a Desperate Heart (Part Four)

Hospital AU

AU Summary: A fall. A single fall. It may seem like nothing until it’s all consuming. What happens when the doctors struggle to diagnosis the disease responsible for Virgil’s rapid deterioration?

Characters: Virgil, Patton, Roman, Logan.

Pairings: Moxiety and Logince.

Word Count: 1830

Warnings: Swearing, death, and speaking about it (not main character death).

Chapter 1 | Chapter 2 |  Chapter 3 | Chapter 4 | Chapter 5 |

     “Logan... Lo-”

    “What Roman!” Logan snapped, whipping his head Roman’s way. Sweat dripped down his brow as he kept pressing the heel of his interlocked fingers down.

    “He’s been down forty-three minutes,” Roman said softly, fingers latching onto Logan’s arm.

    To his dismay, Logan roughly shook off his grasp. Nothing was working; the defibrillator atop the crash cart had done nothing to restart the child’s choked heart.

    Training his jaded eyes back onto the monitor, Logan watched on as the desperate pressing of his hands forged fleeting peaks. Ceasing again, Logan rattled his fist, his nails digging gratingly into his sweaty palm. And the crests were rapidly replaced with the shrill of the flatline buzz.

    ‘Fuck,’ he cursed under his breath, disregarding the throbbing ache in his arms and the sticky feeling of sweat hugging his skin as he began compressions again. The line of nurses waiting to take over had dwindled. And instead, tired eyes watched Logan’s adamant refusal.  

    “Logan,” Roman hesitated to reach out a second time, but the larger the crowd of patients that framed them, the faster he knew he needed to bring it to an end, “Lo, you need to stop.”

    “People have come back after having been down for longer,” Logan countered, rhythm faltering and voice strained.

    “Lo.., he’s been deprived of oxygen for too long.”

    Logan knew Roman was right. The longer the brain was deprived of oxygen, the worse the damage would be. Logically, he should stop. He should stop. What he was doing defied logic. But reason, faulty or not, told him that there was a chance; he’d seen it happen before. So, no, he can’t stop from pressing the heel of his palm down. He-

    “Stop, Logan,” Roman firmly grabbed Logan’s sweat-slicked arm, dragging him off the patient and onto the tile floor.

    “No-,” Logan spat coldly, trying to tug his arm free from the attending pulling him away, but that didn’t halt Roman from tugging him further as the monitor shrieked out a dying cry. It screeched at him, wailed at him, and squawked at him. And he wilted. He wilted hearing the shattering whine of the flatline. And he stopped fighting. He slumped, watching the nurses’ unplug the heart monitor; the call of the monitor vanishing like ships crossing the Bermuda triangle. Absent was the rise and fall of the child’s chest, and absent was the reassuring beep. Instead, reassurance was replaced by machine wheels being dragged away along scratched floors.

    Teal lips and muted, cold skin glaring at him from the corner of his eye sunk their teeth sharply into his memory. But what had, had tears springing into the corners of his eyes was the withered flower visage, the sagged shoulders, and the child’s arms limp at his sides. It was seeing them shelter the child in a flimsy, white sheet that caused Logan to truly depress.

    “F-Fuck off, Ro,” Logan shook, finally yanking his arm free. Stumbling, he turned, wiping away the tears before anyone could see them leave wet trails in their wake.

    “Logan-”

    Logan cleared his throat, shifting, and abruptly cutting off Roman.

    “The beta-blockers should have worked,” He, then, said all too controlled, fists clenched and watching on stiffly like a switch had been flipped. The Propranolol should have worked. Why hadn’t it worked?

    “I know, Lo,” Roman frowned with unease, guiding them both down the achromatic hallway. He’d never observed Logan as anything other than the stoic, calculating logicistian he so frequently gloated on being... “You know you didn’t do anything wrong, right?” Roman watched the other scrunch up his nose as if he’d been asked to try escargot.

    “The facts would seem to suggest otherwise,” Logan scoffed under his breath.

    “I know you know that sometimes people can’t be saved,” Roman opted to use logic against him as he ushered him through the mess room’s ajar door.  

    “I’m aware.”

    “Then you’d know it wasn’t your fault. Sometimes we just lose patients,” Roman said, shutting the door and steering Logan’s stiff frame to sit on the mattress beside him.

    “Yes, well-” Logan muttered, peeling away from the look Roman offered children to comfort them through a particularly painful injection, “I haven’t.”

    “Never?”

    “That is what I said.”

    When Roman fell silent, Logan glanced back at Roman to see his mouth curled downward like a bad omen. He was about to speak up when Roman suddenly interjected, “Do you know why I went into pediatrics?”

    “You’re too exuberant and animated for any other field,” Logan joked jadedly, scooting back further onto the bed, the mattress faintly creaking underneath him as he did so.

    “No- well, it does help with dealing with children, but no, that's not the reason,” Roman shook his head, a choked laugh caught in the back of his throat.

    “Why then?”

    He’d piqued Logan’s interest, but Roman had fallen silent a second time - two times too many. For a man that was so boisterous and noisy at every possible opportunity, him sitting there with his hands resting limply in his lap was unnerving. It was far from the childlike energy he typically exuded.

    “...Roman?”

    “In my third year of med school.., I was assigned a pediatric oncology rotation-”

    “I do remember you mentioning that quite a few times. It would appear it had an impact on you.”

    “Yes...,” He wasn’t past the point of return, but in a moment of trust he proceeded, “but I’ve never told you about Layla.”

    “Layla?”

    “She was the bravest princess,” Roman smiled ruefully, head lolling forward slightly, “She adored my marvelous story telling; her favorite tale was the battle of the dragon witch and the strong, fearless princess!”

    Pausing to collect himself as history painfully nudged its way into the present, Roman continued, “Oh, Lo, if only you could have seen the dreams reflecting in her eyes and the way she lit up every room with her contagious smiles.”

     “More contagious than dear Patton’s!” Roman’s fragile smile straddled the edge of sinking again as his fingertips swiped away new tears over old memories.

    “What happened to Layla, Roman?”

    “She had acute myelogenous leukemia...,” he let out a shaky sigh as he reached into the past to tug those memories looser. Memories of Layla were fragile treasures, priceless glimpses of hope. Memories of her enacting a battle with Roman and striking him with a foam sword before she was too sick to get out of bed weren’t allowed to simply fade away. Those memories once left his heart mangled and weeping. But memories of Layla going wide-eyed as Roman spoke frivolously of the adventures of Princess Fiona and of Layla giggling wildly as Roman’s attending poked fun at him sprung forward with dizzying speed; short, happy time capsules of history nestled in Roman’s mind.

    “She was nine, Lo, and I blamed myself. I was the one that encouraged the transplant.”

    “But you know what?” Roman continued, drying his downcast eyes with his white sleeve, “she helped me; her story shaped mine.”

     When Logan didn’t say anything, Roman resumed, his voice freckled with an incurable ache, “There was a time when I tried to shake the memories because it hurt. It pained me too much, but it was Layla that made me fight for pediatrics.”

    And a silence fell over them.

    “I- I.. I don’t know what to say.”

    “Lo, what I’m trying to tell you is that we can’t save everybody no matter how hard we try, and I know you won’t admit how much it’s eating at you and how much it’ll eat at you because ‘it defies logic’, but I want you to get it into your brainiac head of yours that you’re not alone.”

    Glancing over at Roman, Logan saw the fences torn down by the man himself, “I- Thank you, Roman.”

-------

    “Ye- yes, Patton,” Logan nodded quickly,  interrupting Patton’s distressed rambling, and eyeing the way Roman disappeared back into the E.R., “I am fine. It was just a moment of weakness.”

    “Having emotions isn’t a weakness.”

    “Emotions are messy and unpredictable and precarious.” Emotions were far from the safe clutches of reasoning and deduction; emotions just weren’t Logan’s thing.

    “You shouldn't feel guilty or view having feelings as a weakness,” Patton set the fact free from its fetters, “sure, sometimes, your feelings may not make sense, but it's not your feelings job to make sense. You just... experience them. And you have to do your best to deal with them.”

   Logan stopped, pondered even, only to recycle pages of his own inadequate words and cycle through dozens more he wouldn’t share.

    “Yeah?” Patton cocked his head, picking up again, “understanding them and being in touch with them can give us a better outlook on our issues and our situations. And by understanding how they influence us, we can better evaluate ourselves.” He could tell he was starting to sway Logan, but Logan had long ago cocooned himself in the safety of rationality.

    “Have you heard of Antonio Damasio?” Patton pursued changing Logan’s mind like he chased after a second cookie.  

    Logan shook his head.

    “Well, Antonio Damasio noticed that when his patients lost the part of the brain that controlled emotions, the patients’ decision making abilities became very poor. So, where would we be if we didn’t have the emotional side of our brains?”

    “Huh...” Logan furrowed his brow, eyeing Patton incredulously, “you seem to make a sound argument, Patton.”

    “Hmm....,” after another wordless moment of careful contemplation, Logan spoke up again, “it would seem you are.. right, Patton.” Patton was right? What..? Patton was right...

    “Oh my juice! Really?” His spirit danced with reason to celebrate, lips stretched into a shocked grin.

    “...Yes,” Logan admitted, though he much preferred not having to say it a second time. It was like pulling teeth to hear him verbally acknowledge when he was wrong, but maybe that’s what made it so astonishing to hear.

    “Come ‘ere, hug time!”

    “Fine..” Logan grumbled, letting Patton wrap his arms tightly around him, his own limbs trapped underneath the sweet sunshine’s arms circling his torso.

    “Just know that I’m here for you, Lo,” Patton squeezed, looking up at Logan before letting go. He knew Logan didn’t particularly enjoy long hugs even if they were from him.

    “Thank you, Patton.”

    “Now, how about we go get a nice warm cup of hot cocoa?”

    “That would be satisfactory.”

    “Yay! Let’s g- Oh-” Patton started and then stopped, cogs turning before setting his own universe back in motion, “maybe I should see if Virgil’s up first? You did say you wanted me to keep an eye on him. Last time I checked in on him it was three ish?”

    “That’s right,” Logan said, waving his hand, “go ahead, Patton, I’ll meet you in the cafeteria.”

“Okay! I’ll be right behind you!” Patton leapt into motion with a pep in his step. He’d done good.

Tag list (ask to be added): @buckydeangirl91 @bunny222

[cathygeha]

REVIEW

The Good Kill by Kurt Brindley

A Killian Lebon Novel #1

Do the ends justify the means? Is killing every the right thing to do? Who deserves death? Should death be simple? Is torture ever okay? And, is a person who takes justice into his or her own hands with the intent of killing someone evil ever in the right? Just a few of the questions I asked myself as I read this book.

The book begins with the brutal execution of a man who had no remorse and was as evil as they come. The “Killer” was a man who used his skill-set to to remove evil sex traffickers from the earth...and he really does an excellent job of it. Some of the scenes are graphic and violent and some might not be willing to read such but within the context of this story it does make sense.

Killian Lebon is a man who has served his country for two decades and when he is injured on a mission and can no longer serve he finds a way to feel useful and serve the world though some might question the way he moves forward with his life. His story is told in flashbacks (a few of them) that mention his service, his last mission and why he does what he does.

This book has many characters in the beginning and flipped back and forth between past and present as well as between threads of the story. The threads are eventually brought together and tied up in the end but it took me a bit of time to see what all of the threads had to do with one another.

In addition to the vigilante justice aspect of the book there are women to save, Russians to thwart and the beginning of a potential romance that may or may not bloom into something more if/when the series continues. I am hoping Killian will eventually find peace and a safe place to land.

Did I enjoy this book? Yes

Would I read more by this author? Yes

What might I recommend? Perhaps some editing to reduce the page count to make the story a bit tighter/move more quickly.

Thank you to NetGalley and Books Go Social for the ARC – This is my honest review

4 Stars

BLURB

A former Navy SEAL turned vigilante hitman already in the crosshairs of corrupt Russian agents finds himself in even deeper trouble after rescuing a sex trafficking victim against her will just as she is about to be delivered into the hands of an unscrupulous corporate mogul, an impetuous and dangerous man who will not be denied his purchase. . .

★ ★ ★ ★ ★

During the battle to liberate Mosul from the brutal grip of the Islamic State, Killian Lebon, a war-weary Navy SEAL Senior Chief, sustains life-threatening injuries from an explosion during a rescue operation that goes horribly wrong.

Forced into early retirement from a vocation that for almost twenty years had been his sole purpose for being – that of a fearless warrior in defense of his country – Killian’s life quickly spirals downward to the deepest depths of hopelessness and despair due to the traumatic after-effects of his injuries and the overwhelming guilt he feels from the tragic consequences of his failed final mission.

Left without the will to continue on within such a dark and indifferent world, Killian attempts what he expects will be his last and ultimate mission. But RJ, a woman he had loved once long ago, saves him from his void of despair and, in her effort to console him, reveals two long-held, painful secrets, secrets that inspire within him a dark new purpose for living.

However, it isn’t long before this new lethal life mission of his places him and those he cares for straight within the deadly crosshairs of corrupt Russian agents and unscrupulous corporate moguls and forces him on a desperate and harrowing journey of rescue and revenge, one that takes him from the lush rolling hills of his Southern Pennsylvania farm, down to the mean streets of Baltimore and the steamy bayous of New Orleans, and then back once again to the windswept desert of Iraq where all his troubles first began… and where his most anticipated act of vigilante justice is destined to be executed.

★ ★ ★ ★ ★ THE GOOD KILL Storyline Checklist Battle weary Navy SEAL ✓ Fearless, kickass women ✓ Corrupt corporate moguls ✓ Conniving Russian agents ✓ Ruthless ISIS terrorists ✓ Cold-hearted pimps ✓ Low-life sex traffickers ✓ Evil henchmen ✓ Traitorous scum ✓ Dark Web hackers ✓ Cool cars ✓ Luxurious yachts ✓ High-speed chases ✓ Heartless violence ✓ Brutal redemption ✓ Love ✓ Romance ✓ Kittens __

AUTHOR BIO

A husband and father of three, Kurt Brindley is also a retired sailor who lives in Southern Pennsylvania in a house on top of a windy and rolling hill. He traveled much of the world while serving in the navy and, aye, he's got some stories to tell... Kurt served twenty years and four days in the navy and "retired" as a Senior Chief Petty Officer. He has an undergraduate degree in English from the University of Maryland and a graduate degree in Human Relations from the University of Oklahoma. In 1998, he took a hiatus from his regular duties as a navy telecommunications specialist to attend the U. S. military's Defense Equal Opportunity Management Institute. The institute is little known to most but is internationally renowned to those in the human relations field. Upon graduation, Kurt was certified as a Navy Equal Opportunity Adviser and assigned the responsibilities of providing diversity management training and equal opportunity consultation and assistance to navy personnel throughout the navy's Western Pacific area of operations. Much of this work focused on awareness and outreach seminars in an effort to mitigate the harassment and abuse that resulted from the confusion and resentment surrounding the military's Don't Ask Don't Tell policy. Kurt's assignment as an EOA was one of the most challenging, and rewarding, assignments of his navy career, and it served as the impetus behind much of his early writing, including his novel THE SEA TRIALS OF AN UNFORTUNATE SAILOR and his short story "Leave." With the navy six years in his wake and a promising business career charted before him, Kurt was diagnosed with Chronic Myelogenous Leukemia in Blast Crisis, triggered by the rare Philadelphia Chromosome abnormality, in November of 2009. Blessed by a matched, unrelated donor, he received a bone marrow transplant in April of 2010. Unfortunately, as a nasty side-effect of the transplant, he was diagnosed with an aggressively fatal lung disease in November of the same year. Kurt wasn't given much chance to survive the lung disease -- but he did. It is from this grace-filled experience that he gratefully recounts the lessons he learned about life and how to go about living it in his newly released book HOW NOT TO DIE: In 13 Easy Steps. When not telling stories, reading, or attending to his young, wily, and rather large Plott Hounds Zeno & Aurelius, he often wanders down to the bottom of his hill to walk along the countryside's many rushing creeks and silent still ponds. He likes it there down by the water...

WEBSITE: http://kurtbrindley.com

[healthcare-market]

Chronic Myelogenous Leukemia Treatment Market Will Escalate Rapidly in the Near Future

The demand within the global market for chronic myelogenous leukaemia treatment has been rising on account of advancements in the worldwide healthcare sector. The presence of a robust domain for cancer treatment is expected to improve the chances of market growth. The vendors operating in the global chronic myelogenous leukaemia treatment have made concerted efforts to improve their revenue index. The relation of the global chronic myelogenous leukaemia treatment market to the healthcare industry is a key consideration for the market vendors. The established vendors have succeeded by tying up with leading medical institutes and healthcare facilities. Furthermore, research and development activities in niche areas have also improved the growth stakes of the leading vendors.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34940

It is expected that the global chronic myelogenous leukaemia treatment marker would witness new mergers in the years to come. This projection is based on the quest of small vendors to turn lucrative by joining hands with the large and established companies. Furthermore, the global chronic myelogenous leukaemia treatment market is also expected to witness the entry of new vendors in the years to come. The entry of new players in this market is slated to fragment the global chronic myelogenous leukaemia treatment. Some of the key vendors in the global chronic myelogenous leukaemia treatment market are Teva Pharmaceutical, Novartis, Bristol Myers Squibb, Pfizer, and Hoffman-LaRoche and Schering Plough.

Transparency Market Research (TMR) finds that the global chronic myelogenous leukaemia treatment market would expand at a starry CAGR of 6.7% over the period between 2017 and 2026. Furthermore, the global market for chronic myelogenous leukaemia treatment is expected to touch a cumulative value of US$ 8,550.8 million by 2026-end. On the basis of treatment type, symptomatic treatment has gained popularity over disease specific treatment. Based on geography, the market for myelogenous leukaemia treatment in North America has been rising at a stellar pace.

Request for Analysis of COVID19 Impact on Chronic Myelogenous Leukemia Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=34940

Advancements in the Healthcare Industry to Aid Market Growth

The global market for chronic myelogenous leukaemia treatment has been expanding at a stellar pace over the past decade. The commencement of new trends in the healthcare fraternity is responsible for the growth of the chronic myelogenous leukaemia treatment market. Furthermore, disease treatment is a sub-domain within healthcare that has garnered the attention of regional and international investors. This factor has brought in voluminous revenues into the global chronic myelogenous leukaemia treatment market in recent times. Advancements in the field of oncology have also reeked of growth within the global chronic myelogenous leukaemia treatment market in recent times.

Buy now Chronic Myelogenous Leukemia Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=34940&ltype=S

Popularity of Branded Drugs to Propel Market Demand

Owing to the effective marketing tactics adopted by major drug manufacturers, the demand for branded drugs has been on a rise. This factor has also created tremendous opportunities for growth within the global chronic myelogenous leukaemia treatment market in recent times. Hospital pharmacies have become key sellers of drugs and therapeutics for the treatment of chronic myelogenous leukaemia. This is another key dynamic of growth prevailing in the global chronic myelogenous leukaemia treatment market. It is expected that the market forces of demand and supply would favour the inflow of revenues into the global chronic myelogenous leukaemia treatment market.

The review is based on TMRs’ report titled, “Chronic Myelogenous Leukemia Treatment Market (Treatment Type - Disease Specific Treatment, Symptomatic Treatment; Distribution Channel - Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies; Drug Type- Branded, Generic) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2026”.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/topical-oral-medications-core-of-acne-scar-treatment-market-growth-trajectory--tmrs-study-301341979.html

https://www.prnewswire.com/news-releases/increase-in-focus-on-use-of-advanced-technology-for-drug-development-research-activities-to-drive-global-biosimulation-market-finds-tmr-301348168.html

https://www.prnewswire.com/news-releases/rise-in-use-of-technologically-advanced-products-in-orthopedic-disease-treatment-creates-lucrative-avenues-for-orthopedic-devices-market-opines-tmr-301355874.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com/

[sapanas]

Leukemia Therapeutics Market 2020 Trends, Global Analysis With Focus On Opportunities, Comprehensive Plans And Growth Potential

Market Report Titled "Leukemia Therapeutics Market Research Report – Forecast to 2023" is a Specialist Examination Report Explores the Market by Research Methodology, Segmentation, Key Players, and Major Region Globally.

Leukemia Therapeutics Market Analysis

Global leukemia therapeutics market is growing pervasively and will continue to do so in the years to come due to the growing prevalence of leukemia. With considerable advancements in biotechnology, various innovative therapies have emerged, which drive the market growth excellently. The proven efficacies of these therapeutics in providing effective treatment for leukemia are allowing the market to accrue exponentially on the global platform. Well-spread awareness about leukemia therapeutics has spurred the growth of the market.

Rising numbers of medical science and biotechnology companies is a major driving force behind the growth of the market. Besides, the improving outlook for leukemia treatments that are controlling the spread of the diseases fosters the market growth phenomenally. According to Market Research Future (MRFR), the global leukemia therapeutics market had valued at USD 10.7 BN in 2017. The valuation is further projected to appreciate at 5.3% CAGR during the assessment period (2018-2023).

Read more news on: https://www.medgadget.com/2020/08/leukemia-therapeutics-market-to-grow-at-a-cagr-of-5-3-by-2023-covid-19-impact-analysis-top-comapnies-pfizer-inc-glaxosmithkline-plc-novartis-ag-bristol-myers-squibb-company-sanofi-s-a.html

The rapid adoption of leukemia therapeutics and increasing demand for effective treatment methods are driving the growth of the market. Additional factors, such as increasing numbers of R&D initiatives, clinical trials, and new approvals, are contributing to the growth of the market. Providers are collaborating with independent research centers and hospitals to bring novelties into therapies, which, as a result, are acting as major tailwinds for market growth.

On the other hand, high costs and lack of awareness are projected to impede the growth of the leukemia therapeutics market. Nevertheless, increasing numbers of drug discoveries would support market growth throughout the assessment period. Rapid uptake of these therapies by medical professionals, as well as patients and increasing success rates, are driving the market.

Leukemia Therapeutics Market - Segments      

The market is segmented into three main dynamics to widen the scope of understanding,

By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.

By Application: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.

By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.

These therapeutics are used to treat a range of leukemia types, including acute myelogenous, acute lymphocytic, chronic lymphocytic, chronic myelogenous, and others. Among these, acute lymphocytic leukemia (ALL) is the largest segment in the market. The prevalence of this type of leukemia is the major reason behind the growth of the segment. Additionally, rising numbers of clinical trials and regulatory approvals push the segment growth. For instance, recently FDA approved blinatumomab, a bispecific T-cell engager (BiTE), as an effective method to treat patients with acute lymphocytic leukemia.

Leukemia Therapeutics Market  - Regional Analysis

North America dominates the global leukemia therapeutics market, heading with an increase in the prevalence of leukemia and the geriatric population. Besides, the presence of many well-established players, alongside innovative therapies is estimated to drive the leukemia therapeutics market in North America. The market growth is predominantly supported by the US market, which is growing due to the large patient pool and high healthcare expenditures.

Moreover, technological advancements and well-spread awareness about the availability of leukemia therapeutics, support market growth. The North American leukemia therapeutics market is projected to retain its dominance in the global market throughout the review period.

Europe stands second in the global leukemia therapeutics market. Increasing numbers of leukemia patients in the region drive the regional market predominantly. Furthermore, increased numbers of advanced treatment facilities, alongside the availability of skilled medical professionals and the government support for research & development, fosters regional market growth.

The Asia Pacific region is emerging as a promising leukemia therapeutics market. Factors substantiating the market growth include increasing prevalence of leukemia and spreading awareness among people about the condition and availability of new treatment methods. China and India are proliferating markets for leukemia therapeutics, which contribute to the market growth in the region, majorly. The APAC leukemia therapeutics market is expected to grow phenomenally.

Global Leukemia Therapeutics Market - Competitive Analysis

The leukemia therapeutics market appears fiercely competitive due to the presence of many well-established players. Significant investments are transpired in the field to bring innovations to the therapy and clinical trials. To gain a larger competitive share in the market, these players incorporate strategies such as partnerships, collaborations, mergers & acquisitions, expansions, and technology launch.  

Leukemia Therapeutics Market Major Players:

Players leading the leukemia therapeutics market include Pfizer Inc. (US), Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Takeda Pharmaceutical Company Ltd (Japan), Amgen Inc (US), Hoffmann-La Roche AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), and Sanofi SA (France), among others.

Leukemia Therapeutics Industry/ Innovation/Related News:

March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS).

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.

[ratiram]

According to the report analysis, ‘Global Hydroxycarbamide Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024’ states that there are there are numerous key players which effectively functioning in the hydroxycarbanmide market for leading the highest market growth and dominating the high value of market share across the globe in the coming years while delivering the better consumer satisfaction and developing the working techniques includesBristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, ZydusCadila, United Biotech, Par Pharma, Khandelwal Laboratories, Alkem (Cytomed), Samarth Pharma, VHB Life Sciences and several others. Moreover, this also deliver the effective information related to the profit margins, profile of the players, consequences, benefits, growth opportunities, growth drivers, applications and market analysis by the region.

The Hydroxycarbamide is also well known as Hydroxyurea, is a medication utilized in the chronic myelogenous leukemia, sickle-cell disease, cervical cancer and polycythemia vera. However, in the sickle-cell disease it augments the hemoglobin and depletes the number of attacks. It is taken by the mouth.

In 1967, the hydroxycarbamide was permitted for the medical use in the United States. It is accessible as a generic medication. Moreover, it is on the World Health Organization’s List of Essential Medicines, many efficient and safe medicines required in a health system. Furthermore, the hydroxycarnamide has been utilized generally for the cure of the myeloproliferative diseases, which has a characteristic perils of shifting to acute myeloid leukemia. The potential players of the hydroxycarbamide are playing an effective role for in decreasing the side-effects and increasing the demand of this.

Furthermore, the large enterprises in this market are implementing the profitable approaches for enlarging the business premises across the globe and investing the effective amount for deliver in the better consumer satisfaction and increasing the requirement for this around the globe during the short span of time.

Nonetheless, the cataloguing of the Hydroxycarbamideinvolves the capsule and tablet, and the proportion of capsule in 2016 is nearby 63%, and the quantity is in diminishing trend from 2012 to 2016.Whereas, the Hydroxycarbamide is extensively utilized for the sickle cell disease, cancer and several other disease. The major proportion of the Hydroxycarbamide is effectively utilized for the sickle cell disease, and the proportion in 2016 is 45%.

Based on the region, the market of hydroxycarbamide is spread across the globe which majorly includes North America, Europe and Asia-Pacific, South America, Middle East and Africa. However, owing to the significant advancement in the technologies the industrialized regions dominate the market.

For instance, the Asia Pacific is the principal purveyor of the Hydroxycarbamide, with a manufacture market share approximately 59% in 2016.

The Middle East and Africa is the principal consumption place, with a consumption market share practically 36% in 2016. Following Middle East and Africa, Asia Pacific is the second foremost consumption residence with the consumption market share of 20%.

The Market competition is not penetrating. The Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, ZydusCadila, United Biotech, Par Pharma, etc. are the foremost leaders of the industry, and they hold the key technologies and patents, with high-end consumers; have been designed in the monopoly situation in the industry. Therefore, in the near future, it is anticipated that the market of hydroxycarbamide will increase across the globe more significantly over the decades.

For more information on the research report, refer to below link:

Global Hydroxycarbamide Market 2019

Related reports

Global Hydroxycarbamide Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Global Hydroxycarbamide Market Status and Future Forecast 2015-2024

Contact Us:-

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

+91-9015378249

[healthcare00897]

Antibody Drug Conjugates Market: Shows Increasing Demand To Be Observed In The Coming Decade

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug.  

Get Exclusive Sample Report at: http://bit.ly/2RPnqbV

By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.

Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market

In terms of marketing, three antibody drug conjugates have received regulatory approval.  The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.

Antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the market to two digit billion dollar mark by 2020

The global antibody drug conjugates market is segmented on the basis of drug and geography. On the basis of drug, the market is divided into Adcetris and Kadcyla.

Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates

Regional segmentation of the antibody drug conjugates market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe accounts for the largest share in the global market mainly due to presence of many contract manufacturing companies with advanced manufacturing equipment. Lonza is one of the top contract manufacturing companies in Europe, which has operations across France and Germany, with its headquarters in Switzerland.  One of the facilities operated by the company is a deck to chemical manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields such as high-class active substances, organic chemicals and intermediates.

Request For Customization of Research Report @  http://bit.ly/2FJ0bLT

Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market

Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

[martynnx-blog]

Chronic Myeloid Leukemia Treatment : Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a blood-cell cancer that begins in the blood-forming cells of the bone marrow. Myeloid cells are a type of immature cells that are capable of making white blood cells and when these cells continue to grow in an abnormal condition, it turns into a chronic myeloid leukemia condition. This cancer majorly causes fatigue, fever, easy bleeding, infection, bone pain, anemia, and swollen spleen among the patients who are middle-aged people or older, though it can occur in children also. CML is a slowly growing leukemia, however, it can also change into a fast-growing acute leukemia, which is harder to treat. Continuous support from the government by approving the pipeline drugs for CML is expected to propel growth of the market over the forecast period. For instance, in February 2014, Teva Pharmaceutical Industries Ltd.’s drug, SYNRIBO (omacetaxine mepesuccinate) for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) got the U.S. FDA approval.

For In depth Information Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1726

Chronic Myeloid Leukemia Treatment Market Drivers

Increasing number of researches that are being carried out to identify the causes of CML cancer is expected to boost growth of the chronic myeloid leukemia treatment market over the forecast period. Targeted drug known as tyrosine-kinase inhibitors (TKIs) have been effective in providing long-term survival rates. Furthermore, the Food and Drug Administration (FDA) approved dasatinib (Sprycel) for the treatment of chronic myeloid leukemia in pediatrics in 2017. Researchers are also focusing on polypharmacology approach to develop drugs that can act on multiple targets. This is leading to the drug discovery opportunities that are beyond the concept of ‘one drug, one target’.

As chronic myeloid leukemia is more aggressive in younger patients, the approval of drugs can help in effective treatment. Moreover, with the development of imatinib and the second generation TKIs, dasatinib and nilotinib, small molecule drugs have become the mainstay for the first-line CML management. However, high cost of the drugs used for this disease is a major restraint affecting the growth of the market. For instance, TKIs drugs are very expensive and therefore, generic drugs are being introduced in various countries. Increasing prevalence of this cancer in various regions is expected to drive growth of the market over the forecast period. For instance, according to an article published in UBM Medica LLC, CML accounts for around 15% of the total leukemia cases in adults. Approximately 8,220 new cases of CML were diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 population.

Chronic Myeloid Leukemia Treatment Market – Regional Analysis

On the basis of region, the global chronic myeloid leukemia market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to gain significant traction in the chronic myeloid leukemia treatment market, followed by Europe, owing to increasing prevalence of chronic myelogenous leukemia in developed economies due to genetic factors. According to the America Cancer Society, around 8,430 new cases of CML will be observed (4,980 in men and 3,450 in women) in 2018 and around 1,090 people will die due to CML (620 men and 470 women). However, improving healthcare infrastructure in emerging economies such as China and India are contributing towards the growth of chronic myeloid leukemia treatment market in the Asia Pacific region.

Chronic Myeloid Leukemia Treatment Market – Competitive Landscape

Tough competition between major players to retain their market share in CML market may provide opportunities to come up with altered solutions in drug development and new strategies to embrace the mindset of the end users. Since 2015, majority of the drugs offered by major players for this condition were approved. There are commercialized products, which include Bristol Meyer Squibb’s Sprycel (approved in December, 2017), Novartis’s Gleevec and Tasigna (approved in March, 2018), Takeda Pharmaceuticals’ Iclusig (approved in 2018), and Pfizer’s Bosulif (approved in December, 2017).

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1726

The market players operating in the chronic myeloid leukemia treatment market include Teva Pharmaceuticals Industries Ltd., Hoffman-La Roche Ltd., Novartis AG, Bristol-Myers Squibb, Pfizer, Inc Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, and Otsuka Pharmaceutical Co., Ltd among others.

[addictionfreedom]

Dual Diagnosis Treatment Centers Houston Texas

Contents

162nd street north miami beach

Perineural tumor spread

Professional medical advice

Diagnosis residential treatment programs

Addiction treatment center … communities

University Cancer Centers are state-of-the-art cancer treatment facilities in Houston, Texas. University Cancer Centers has a long and continuing history of excellence in cancer diagnosis and treatment. Award winning board certified Radiation Oncologist, Mark D'Andrea, MD and his team are…

GONZALEZ is an Assistant Professor of Education Psychology and Texas … of Houston. Working closely with Deborah Simmons, she focuses on instructional features that promote language learning for chil…

Drug Treatment Centers Texas what do you really want for your life? Take time to explore the vast amount of resources available to you, as our Texas network is constantly growing. By taking the time to explore your options, you can finally put an end to addiction.

Our dual diagnostic treatment centers treat all of these conditions concurrently, enhancing each patient's likelihood of achieving a full recovery. Sovereign Health provides patients with top-rated dual diagnosis treatment centers. Following the initial three-step assessment upon admission, our…

Dual Diagnosis Treatment Uk 'Dual Diagnosis' is the term used when a person suffers from both a substance abuse problem and Most mental health services and addiction treatment centres in Ireland are currently not organised to treat A study by the UK Dept. of Health put the figures even higher, suggesting that 75% of users of… This is a

Intraperitoneal injuries may be missed by both CT and RP, so patients with a high index of suspicion and/or indirect evidence of rectal injury on CT scan may necessitate laparotomy for definitive diag…

Show More From the Departments of Leukemia, Hematopathology, Stem Cell Transplantation and Cellular Therapy, and Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston … Patients wi…

A dual … and treatment without stigmatizing those groups. “Given the stigmatization of TB, our ability to do targeted interactions is limited,” said Dr. Jeffrey Starke, a pediatric tuberculosis phys…

Patient diagnosis is also enhanced … serves southeast Texas and the greater Houston community. Memorial Hermann’s 14 hospitals include three hospitals in the Texas Medical Center, two long-term care …

Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, TX … faster times to CCyR and MMR, fewer on-treatment transformations to accelerated/blast phase, and fewer CML-related deaths …

Addiction Treatment Austin Marijuana addiction doesn't have to run your life. Help is available at our Austin marijuana addiction treatment facility. Drug rehab center infinite Recovery helps addicts recover in Austin at the best client focused treatment facility in Texas. Call Today (844) 206-9063. "I knew he was chatty — a lot of this job is human-to-human interaction,"

Dec 13, 2017 … Houston, TX Drug and Alcohol Rehab Center … is located on 50 acres of a pure Texas landscape; only 45 minutes south of Houston, Texas. … dual diagnosis treatment (addiction with mental health issue). chronic relapse …

Nov 26, 2018 … Programs come in various forms, including inpatient, outpatient, and partial … A challenge for those seeking treatment is that the amount and even the type …. therapist who specializes in dual diagnosis and eating disorders.

Dual Diagnosis Help. Teen Addiction Help. Texas Addiction Information. We offer outpatient drug and alcoholism treatment in several regions across the state including Houston, Austin/San Antonio, and Dallas/Fort Contact our Texas center today for more information on our treatment programs.

Show More From the Departments of Leukemia and Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston … criteria included the following: diagnosis within 6 months from the st…

Aug 5, 2014 … Looking to find the right addiction treatment center in Texas? … addiction and dual diagnosis treatment center, offering treatment services to …

Addiction Treatment Centers In Maine She was paralyzed from the neck down. After 10 days of hospitalization in Falmouth, Maine, where she lived, she was transferr… Find and Locate Maine Addiction Treatment Centers – Get Help Today 1-888-565-6401. Get in touch. Physical Address. G & G Holistic Addiction Treatment 1590 NE 162nd street north miami beach, Florida 33162 United States.

Co-occurring mental health issues can make it hard to overcome addiction. Discover how our transformative Texas dual diagnosis treatment center can help you …

Anderson Cancer Center, Houston, TX. A subset of patients with chronic myelogenous leukemia (CML) do not respond to the … Gene expression profiling of CML at diagnosis for PTGS1 may be useful in pre…

ERC offers best-in-class treatment programs for all patients, no matter their age or gender, struggling from: anorexia, bulimia, binge eating disorder, eating and weight disorder, unspecified eating d…

Dr. Steven Petak is an endocrinologist in Houston, Texas and is affiliated with Houston Methodist Hospital. He received his medical degree from University of Illinois College of Medicine and has been …

We used a dual-color analysis with probes from tumor and reference being differentially labeled by cyanine 3 and 5. Pan-genomic DNA BAC-microarrays (1 Mb resolution) were obtained from Spectral Genomi…

Our purpose was to familiarize the reader with the anatomy of this nerve and imaging’s potential role in the diagnosis of perineural tumor spread along this seldom seen structure. The great auricular …

Our Houston drug and alcohol rehab center offers licensed clinical services such as detox, IOP, supportive outpatient treatment, and aftercare, which are …

The Menninger Clinic is a leading specialty psychiatric hospital that treats adults and … Facebook Live Event to Focus on Early Diagnosis and Treatment of Autism … Learn how our treatment programs and services for adults, young adults and …

Dual diagnosis treatment should be led by specialists who are expert at diagnosing it and designing effective treatment regimens to overcome it. Sovereign Health of Texas is one of the nation's top dual diagnosis treatment centers offering hope and recovery to patients struggling with this condition.

The Memorial Hermann Prevention and Recovery Center (PaRC) is a … Located in Houston, Texas the program and staff provide the highest level of quality of care … substance abuse and dual diagnosis treatment for adults and adolescents .

A state-of-the-art PHP and IOP serving The Woodlands, Texas …. We specialize in dual diagnosis treatment, addressing the substance use disorder along with …

Jun 23, 2016 … Locations of Substance Use Program Centers in Texas … Faith-based chemical dependency treatment programs provided by religious …

Houston, and Thomas Yorio, PhD, University of North Texas Health Center, Forth Worth. Featured in the issue is the article "Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotens…

Addiction Treatment News Seven public meetings have been held to introduce Doorway-NH, a plan to ensure that Granite Staters are no more than an hour … The U.S. Centers for Disease Control is funding a study led by researchers at the Johns Hopkins University School of Medicine … Oct 29, 2018 … Plus, watch as a cat steals

Mental Health/Dual Diagnosis … Substance Abuse and Addiction Treatment Resources in Houston … Houston, Texas Alcohol Rehab Centers and Drug Centers …. to be a substitute for professional medical advice, diagnosis, or treatment.

Our programs for addiction treatment in Houston, Texas at our leading alcohol and drug rehab center provides a At The Watershed's Houston Texas Drug Rehab Center, you will receive individualized care that The Watershed Addiction Treatment Programs in Houston is a state licensed, accredited…

The city of Houston, Texas has many different tire centers to choose from. Dual Diagnosis treatment is used when a person has an addiction problem along with a mental disorder issue. There are many different dual diagnosis residential treatment programs available throughout the United…

Dr. Eric Chiou is a pediatric gastroenterologist in Houston, Texas and is affiliated with Texas Children’s Hospital. He received his medical degree from Northwestern University Feinberg School of Medi…

Directory of Texas, alcoholism & chemical dependency, treatment centers & programs. Origins Recovery Center – Provides a comprehensive continuum of longer-term inpatient addiction treatment services for adult men and women, including those with serious dual diagnoses.

The location of our inpatient dual diagnosis rehab and addiction treatment center … communities and homes after completing our drug rehab center in Texas.

Dual-Diagnosis Addiction Treatment – By Women, Exclusively for Women … Situated in the tropical environment of South Padre Island, Texas, Hannah's House …

… Texas M. D. Anderson Cancer Center, Houston, TX 77030–4009, USA. 12 Department of Computer Science, Yale University, New Haven, CT 06520, USA. 13 Department of Pathology and Laboratory Medicine, W…

A 10-point quantitative topographic CT scan score, the Alberta Stroke Program Early CT Score (ASPECTS), is described … Patients were recruited from both Calgary and Houston, TX. For the purposes of …

Addiction Treatment Center Employment I can have a job. I can do whatever I want with my life … German Lopez/Vox arianna sampson helped launch the ER opioid addi… The Treatment Center Employment Opportunities. Are you looking for a rewarding job in the healthcare and addiction treatment industry? Our success would not be possible without our greatest asset: our

The performance of dual-energy x-ray absorptiometry (DXA) in identifying children with … The institutional review board of St. Luke’s-Roosevelt Hospital Center approved all studies. Body weight was …

Treating a dual diagnosis requires comprehensive assessment and care. Houston, and surrounding areas, boasts several prominent rehab centers which offer The Treehouse is a residential drug and alcohol treatment center and can be instrumental for those who have fought substance addiction that…

Dual diagnosis treatment is a treatment methodology that treats substance abuse in conjunction with a co-occurring mental health disorder. Treatment-Centers.net is a public benefit service which provides drug addicts, alcoholics, dual diagnosis sufferers, and individuals suffering from other…

Find private, inpatient rehabs in Houston, Texas including some of the Nation's … See All Results Show me the Top Rated Treatment Centers in the US …… Dual diagnosis refers to someone who is simultaneously coping with drug or alcohol …

For its part, the University of Texas MD Anderson Cancer Center in Houston … from treatment, Anselmo hasn’t experienced any side effects. (Like Stiefel, she lost most of her hair during radiation, w…

6 Department of Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA. ↵* Present address: Department of Veterinary and Biomedical Sciences, University of Minnesota, S…

ADA WOMEN'S CENTER RESIDENTIAL TREATMENT PROGRAM. (click here for … 10525 Eastex Freeway Houston, TX 77093. Harris County … DUAL DIAGNOSIS PROGRAM. (click here for …. VOLUNTEERS OF AMERICA TEXAS, INC.

Dual Diagnosis drug and alcohol treatment centers deal with high-risk individuals every day. Those who suffer from coexisting mental and addiction issues are more prone to violence and are more likely to attempt suicide. The staff at these centers must be well-prepared to deal with the unpredictable…

I am a Michigan native, but I currently reside in Houston, Texas. I’m a HIV activist … these HIV criminalization laws that require us to disclose our personal medical diagnosis due to outdated laws …

The Right Step Texas rehab centers offer affordable drug and alcohol treatment for adults and adolescents. Begin residential or outpatient programs today.

The overall goal of our adult dual diagnosis program is to help individuals cope with both substance abuse and mental health Mental Health and Substance Abuse Counseling in The Woodlands area of Houston, Texas. Click on the link below to contact New Dimensions Day Treatment Centers.

We are so glad you found us in your search for the best addiction treatment programs in Texas and nationwide. Reputable addiction treatment in Houston can be …

[dorkwhowrites]

The Wishlist (Chapter 3)

Group: Bangtan Boys

Pairing: Yoonseok/Sope

Genre: Angst/Fluff

Yoongi manages to make it on time today and the first person that he sees is an anxious Jung Hoseok sitting in the waiting area and he jumps out of his seat as soon as he sees him.

“Dr. Min,” he says. “I am…I am ready”

“Uh um all right,” Yoongi says. “Give me a minute”

He just nods and Yoongi goes inside placing his bag and clears out his desk before he opens the door so that Jung Hoseok can come in.

Today, he is dressed in a long-sleeved black shirt and tight ripped jeans and his backpack that he seems to be clutching close to his chest as he sits down.

“So, I have leukemia,” he begins in a very casual tone.

“Yes, acute myelogenous leukemia,” Yoongi completes.

“Oh, that sounds risky,” Jung Hoseok says with a small chuckle surprising Yoongi who didn’t expect to anyone seem so relaxed discussing their disease.

“Well, we have to discuss treatment,” Yoongi says.

“Uh, yeah that,” Hoseok says. “What do you say?”

“Well, you have the option of chemotherapy and radiation,” Yoongi says as he opens his desk and looks for a paper. He finds it and hands it to Jung Hoseok. “Also the hospital is running a clinical trial on a drug; you can be a part of that”

“Not that one,” Hoseok says.

“All right with your subtype of AML, I think you would have to go with the radiation therapy,” Yoongi says.

“How does that work?”

“It basically using radiation to kill cancer cells,”

“Oh,” Jung Hoseok says. “And when should I start the treatment?”

“As soon as possible, I think,” Yoongi says.

“Well I have to accompany my crew to a show today,” Jung Hoseok says. “So can we start after a day?”

“Crew?”

“My dance crew, I run a dance studio,”

“Oh, that’s no problem then,” Yoongi says.

Hoseok smiles.

“Thank you Dr. Min,” he says as he stands up. “I’ll see you later”

Yoongi just nods as the man leaves the room leaving behind a very puzzled Yoongi. He doesn’t know if it is an act or is the other man really that nonchalant about the prospect of dying. Either way Yoongi seems confused by his patient as he lurks around his mind the rest of the day until it is the end of the day and Yoongi is leaving when he feels a hand on his shoulder tightening their grip.

Yoongi looks up to see a smiling Dr. Jackson Wang.

“Min, you look in a hurry,”

“I’m not,” Yoongi says loosening from the other’s grip.

“End of shift?” Jackson asks.

“Yeah,”

“Why don’t you stick around for a bit?” Jackson asks. “I’ve got clinic duty for about half an hour and then we can go have some drinks”

“Wang…,”

“Don’t say no,” Jackson says. “It’s been too long since we sat down and talked. I miss you man as gay as it sounds”

“All right fine,” Yoongi sighs.

“That’s better,” Jackson says. “I’ll be right back though”

Yoongi nods as he just sits in the waiting room too on his phone until Jackson finally shows up only to be stopped by one of the nurses and they talk to each other in hushed voices for a good ten minutes until Jackson leaves winking at her and Yoongi rolls his eyes.

“So is that your new interest?” Yoongi questions.

“She’s cute,” Jackson says.

Yoongi doesn’t say anything as they get in his car and starts driving while Jackson changes radio stations every five seconds before turning it off completely.

“All they play is shit lately,” he says.

“Yeah,” Yoongi says as he continues to drive and they soon reach the bar that they usually hang out and since it’s a weekday Yoongi manages to find a parking spot.

“I am not gonna drink a lot, I still have to get home,” Yoongi says.

“Yeah, yeah,” Jackson says as they enter the bar.

They end up sitting on one of the far corners of the bar and Jackson skims the menu while Yoongi looks around to see men and women who seem to be in their early twenties at the most. It makes him feel self-conscious.

Jackson orders some kind of weird cocktail and while they wait for it Jackson leans in whispering.

“See the chick in the back,” he says.

Yoongi cranes his neck and sees a woman dressed in a purple mini dress sucking on a straw. She looks 25 at the most and as their eyes meet she looks away.

“Yeah?”

“She has been staring at you for the past 15 minutes,”

“Oh,” Yoongi says.

“Go make a move,”

“I don’t want to,”

Jackson sighs.

“Min, come on, opportunities like this don’t really show up,” Jackson says.

“Well, I would like to let the opportunity go away,”

Jackson rolls his eyes as the waiter brings them the drink.

“Excuse me,” Jackson says to the waiter. “He would like to buy a martini for the lady over there”

Jackson points at the purple lady and the waiter just nods leaving.

“Jackson what the fuck,”

“You are getting laid tonight,” Jackson says.

Yoongi sighs as he sips his drink dreading the conversation he would have to have with the lady. He would, of course, find some way and get out of it. He had to.

“Holy shit, she is coming here,” Jackson says. “Min, this is your moment”

“I hate you,” Yoongi mouths at Jackson as the woman approaches them smiling.

“Hey,” she says looking at Yoongi.

“Hi,” Yoongi says.

“Do you mind?” she asks Yoongi to let her sit and Yoongi simply scoots over while Jackson looks smug that his plan seems to be working.

Of course, Yoongi is supposed to say something to her, start the conversation and talk about her, make her giggle while she gets drunk so he could take her back to his flat and the fuck her brains out.

No, of course not, not in Yoongi’s life at least as he looks at his watch with a small frown on his face.

“I…I would love to talk to you,” he says. “But I gotta pick up the kids”

“Kids?” she asks with a frown.

“Uh yeah, would you excuse me?”

She stands up letting Yoongi go who grabs his coat and then leans down to whisper into Jackson’s ear.

“She’s all yours,”

Yoongi leaves the suffocating bar. He loves drinking but more in the privacy of his home where he lets a few tears spill. He gets into his car and drives back home where he spends the rest of the evening cooking an elaborate recipe he found online just because it kills time and by the end of the night he is already through two bottles of beer but at least he sleeps better than most nights.

The next day Yoongi is visibly hungover as he walks with his head hung low and he happens to bump into Jackson.

“Min, you look like shit,”

Jackson is glowing.

“You seem happy,” Yoongi says as he grabs his second cup of coffee in the morning.

“Let’s just say, you missed out,” Jackson smirks and Yoongi simply rolls his eyes sipping on the coffee.

“See you later Wang,”

“You too,”

Yoongi goes to his office and just as he takes a seat there is a knock on the door and Jung Hoseok is standing there.

“Mr. Jung come in,” Yoongi says.

He nods as he sits down on the chair while Yoongi does the same. For the first time, Yoongi wonders why does the man always show up alone. It wasn’t unusual for patients to show up alone for checkups but for treatments, there is always someone for support.

“The treatment,”

“Yes, we have to start it from today,” Yoongi says as he takes out Jung Hoseok’s file. “Come on follow me”

Yoongi takes him to the radiology and while they are in the elevator Jung Hoseok fiddles with his hands staring upwards at the ceiling.

When they arrive at the radiology Yoongi calls in a nurse who assists Jung Hoseok to get in for the checkup while Yoongi retreats to the small room with the computer.

“I want you to lie completely still,” he says in the mike.

“Okay,”

“You don’t have any metal on, do you?”

“Uh no,” Yoongi hears his echoed voice.

“All right then,” Yoongi says as the scanning begins and Yoongi looks for the area of the tumor growth.

When the scan is done Yoongi gets up and helps Jung Hoseok out of the machine who seems to be relived as he stands up and stumbles down but Yoongi catches him before he can fall.

“Are you okay?”

“Uh yeah I yes I’m fine,” Hoseok mumbles incoherently.

“Sure?”

Hoseok nods vigorously.

“You should ask someone to come with you…just in case…,”

“I told you,” Jung Hoseok cuts off sounding annoyed. “I am totally fine”

“All right,” Yoongi answers alarmed.

“I um I am sorry,” Jung Hoseok says.

Yoongi just nods as they leave the radiology and head straight back to Yoongi’s office and this time the elevator has people in it so it’s not that awkward. Once they get to his office Yoongi shuts the door and sticks the scan on the little glass above his seat.

“This right here,” he says. “Just around your spinal cord,”

“The tumor?”

“Yes,”

“Oh, so the radiation will kill it,” Hoseok asks.

“That’s what we hope for,”

“There’s no guarantee?”

“…”

“Uh yeah, I get it,” he says. “So when do we start?”

“We have to work out a schedule for you,” Yoongi says. “And you would have to bring your insurance and everything,”

“Okay,”

“You can come tomorrow so we can make time for your sessions,”

‘Sure,” Jung Hoseok says with a small flicker of a smile on his face.

Yoongi presses his lips in a small polite smile as well as Jung Hoseok gets up ready to leave.

“Thank you, Dr. Min,”

Yoongi just nods before he sits down at the desk as he sighs because sometimes he gets tired of telling people that they are gonna die. He doesn’t want to give them false hope but he does want them to live. To see their eyes full of life again and even though there isn’t much he can do about it the thought is always lurking in the back of his mind.

He has seen countless other people like Jung Hoseok.

He only hopes that Jung Hoseok doesn’t meet the same fate.

The next day Jung Hoseok is back at the office and as soon as he sees Yoongi he smiles and Yoongi smiles back because he really likes how positive Jung Hoseok appears to be. Most people lose all hope in their lives when they get the news that they have cancer, understandably so but at least not Jung Hoseok.

“I have all my papers with me,”

“All right,” Yoongi says. “We have your schedule fixed up”

“Oh,”

“It’s gonna be every day for five times a week in the evening,”

“Okay,” Hoseok says. “When do I start?”

“You can start on the coming Monday if you wish,”

“Okay then,” Hoseok says as he looks over at Yoongi’s desk and picks out a yellow card.

“What’s this?” he asks.

“Cancer support group,”

“How does that work?” Hoseok asks.

“Cancer patients come together discuss their problems, lives, thoughts dreams and everything else,” Yoongi says. “So they don’t feel alone knowing that someone shares their feelings”

“Oh,” Hoseok says turning the car in his hands. “Um, can I come?”

“Sure, if you want to,” Yoongi says.

“I feel like I really need to talk to someone,” Hoseok says.

“The support group is a great place to express your thoughts,” Yoongi says.

“It’s on every Sunday evening,”

“Yes,”

“Oh, okay,” Hoseok says as he pockets the card. “I’ll be there”

Yoongi nods as Jung Hoseok leaves with one last smile and he leaves.

The rest of the day passes by and when Yoongi’s shift ends he leaves and finds Jackson talking to the cute nurse and he winks when Yoongi passes by and Yoongi snorts a little as he heads outside to his car.

Since its Saturday he heads straight to Seokjin’s house and finds Seokjin prepping for dinner and Namjoon hasn’t returned from work yet while the kids are circling around Yoongi as he helps Seokjin make the dinner.

“So how was your week?” Seokjin asks.

“It was pretty okay,” Yoongi answers.

Yoongi expects Seokjin questioning him but just then Namjoon comes back from work and a smile spreads on Seokjin’s face.

Namjoon comes in closer and kisses Seokjin gently before hugging the kids and Yoongi smiles to himself suddenly feeling that he is interrupting a very private moment.

Once Namjoon leaves to change Seokjin starts to set up the table and the kids help him and once they are done Namjoon comes back and they have dinner while Namjoon narrates an incident at work which has Seokjin laughing hard.

When they are done with the dinner Yoongi gets ready to leave but not before Seokjin corners him.

“You look a bit off Yoongi,” Seokjin says. “Is everything okay?”

It is really a difficult question and Yoongi doesn’t know how to answer it but he smiles.

“I am fine hyung, don’t worry,” he says.

Seokjin bites his lips before hugging him tightly.

“You’ll always have me worrying for you, you idiot,” he says.

Yoongi just laughs as he says his goodbye to Namjoon and the kids and then hugs Seokjin again before he finally leaves and the smile fades.

Some days are definitely better than the others but today isn’t one of them.

Yoongi is woken up by the phone ringing and he wonders who on earth is calling him on a Sunday morning? It’s 1 pm yes but that’s morning for Yoongi.

He picks up and yawns.

“Dr. Min,” he hears a female voice.

“Yes, “

“I’m Dr. Kim,” she says. “I am actually the doctor who runs the cancer support group”

“Oh,”

“Well, I want to ask you a favor,” she says. “I have an important issue coming up for today and I want someone to take over the session for me but no one seems to be free and I really don’t wanna cancel”

Yoongi thinks about it, yes it could potentially ruin his only day off which he reserves for eating unhealthy takeout and watching TV but it’s just for one day he thinks so he lets out an inaudible sigh.

“Okay, I can do it,”

“Good, thank you Dr. Min,” she says. “I am very grateful”

“It’s no problem,” Yoongi says as he hangs up and stretches his arms. He might as well as a shower if he has to leave the comfort of his house.

After a lunch of sandwiches, he leaves the hospital and reaches there at 4:45 even though the support group is supposed to start at 5 and he finds one person sitting there. It’s a teenage girl wearing a beanie looking off into the far distance she doesn’t acknowledge Yoongi in any way as he sits on the center chair.

Soon people start coming in and they all look at Yoongi with confused looks but stay silent until it’s 5 and he sees the place is mostly filled so he clears his throat.

“I am filling in for Dr. Kim today,” he says.

“Where’s Dr. Kim?” a woman asks.

“She had something important to look after, I believe,” Yoongi answers.

“Oh,” the woman says.

Just then the door opens again and Jung Hoseok is standing looking out of place in his tank top and shorts and his backpack that hangs from his shoulders.

“Sorry, sorry,” he says as he pulls an extra plastic chair and sits down and all the eyes are on him in a very curious way.

Yoongi clears his throat again to get their attention and he succeeds.

“So can we begin,” he says.

“Wait,” a boy interrupts him. “There is no introduction”

“Introduction?” Yoongi asks.

“Every time someone new joins the group we have them introduce themselves,”

“Oh, well then go ahead Mr. Jung,”

Jung Hoseok stands up keeping his backpack down.

“I am Jung Hoseok, 29 years old. I am a dancer by profession and I uh I own a small dance studio and I was diagnosed with leukemia about a week ago,” he says with a dark little chuckle.

“What are your dreams?” the teenage girl with the beanie asks. “Dr. Kim always asks to tell our dreams,”

“I have a lot of them,” he says. “I wanna see places, try things that I’ve never done before”

He continues.

“Of course time is ticking,” he says and Yoongi sees a few people shift uncomfortably in their seats. “But I would like to make them true”

“Dr. Kim always says that believing in your dreams is a healthy thing to do,” a little boy who looks about 12 says. “You shouldn’t give up on them”

“I won’t,” Jung Hoseok says.

“You can sit down now Mr. Jung,”

Jung Hoseok nods as he sits down.

“Dr. Kim,” Yoongi says “Gave me a topic to discuss about. It’s about the time you felt utterly helpless in life and how you got out of this phase. Your struggles and your advice to anyone else who is in the same situation, anyone that would like to volunteer”

Everyone looks at each other but no one seems to be ready to share before a hesitant hand is in the air. It’s the last person Yoongi expects.

“Mr. Jung,” he says. “You can begin”

He nods as he looks at his palms.

“2 years ago,” he says. “Something bad happened. It was unexpected, the death of my parents”

Jung Hoseok continues.

“One day they are fine and we talked about how my first day at elementary school at dinner and the next day I hear they had an accident and they are gone just like that. I would be lying if it wasn’t hard to lose both of my parents at the same time. I couldn’t grasp it. My only family was no more. I was orphaned and all alone in this world. I had absolutely no one for me. The several months after my parents’ deaths were the worst in my life. I had lost all hope and support in my life and I fell into depression”

He takes a deep breath.

“But I decided I wanted to change and that I wanted to live again because I knew that is what my parents would want. I did not stop being sad all at once. It happened over the time as I started to treasure them more for the happy memories instead of the pain that their death had caused me and I started living little by little. And six months ago I finally made the move to Seoul. It has been hard let me tell you and there is not a day that goes by when I don’t miss them but I’ve learned to cope with it and it works…well most of the time”

He slowly wipes the corner of his eyes and Yoongi feels a pang in his heart.

“That was very brave of you to share,” Yoongi finally says as Jung Hoseok just nods.

He sees some of them stand up and going over and hug him or just pat his back and once they are all back to their seats a middle-aged man slowly raises his hand and begins narrating about the time he fell into a dark place with depression and how he came out of it and slowly and steadily a lot of them open up with the varying stories and there are tears, lots of them but there is also comforting words and hugs to offer and Yoongi smiles to a little himself seeing how these people have each other for support.

“Dr. Min,” the beanie wearing teenage girl says. “Dr. Kim would usually share her life experiences with us as well. Would you mind?”

Yoongi is a very secretive person. He rarely opens up and he would usually say no to any situation that required him expressing his deepest feelings to a bunch of strangers but he realizes the support group is different. The people here get naked in a metaphorical way and talk about things that they never would in another setting so he just nods.

It’s not as devastating as the others but it was the darkest moment in his life he thinks as he begins.

“My wife cheated on me. My wife whom I had been married to for 7 years cheated on me. The only woman I had ever loved in my life didn’t take a second to break my heart. Last year around summer time that happened and it broke me to pieces because I never expected her to do that to me. We got divorced and she moved on but I couldn’t because she was my soulmate and we were meant to be together but I guess I was wrong,” he says. “It was a dark time because I thought it was my fault and that I wasn’t good enough and that I never loved her like I should have but it wasn’t me, she just wasn’t in love with me anymore she said to me. We were young when we got married and maybe it was all butterflies and they eventually died down leaving us to nothing”

Yoongi finishes and he is positive that he has never been this open to a bunch of complete strangers ever before that he feels naked and then the middle aged woman stands up and gives him a hug and just like that everyone else offers their support to him in their way and when they are all done Yoongi wants to cry but he doesn’t as he looks at his watch. It’s 7:30 already and they were supposed to end the session a half an hour ago but it dragged.

“I think that is quite enough for today,” Yoongi says. “Thank you all for coming today. I hope you have a good day and a wonderful week”

Slowly the people start leaving and so does Yoongi and he bumps into Jung Hoseok who smiles at him.

“I didn’t know you were in charge of the support group too,”

“I was just a replacement for today Mr. Jung,”

“You can just call me Hoseok you know,” he says. “I don’t mind”

“Okay Hoseok,”

He smiles.

“See you on Monday Dr. Min,”

Yoongi nods as he watches Jung Hoseok walk away and he looks until the other man is out of vision before he too walks to his car and gets into his car and today he feels lighter as if he just dropped something off of his shoulder.

H e feels light.

Maybe it’s talking he thinks. He hasn’t told many people about the whole fiasco with his wife. To Seokjin it was just through a lot of ugly tears and everyone else knew but they didn’t bring it up so Yoongi never had to talk about it and now that he did he feels better than he has ever before.

The support group wasn’t nearly anywhere as disastrous as he thought it’d be.

[sapanas]

Leukemia Therapeutics Market Trends, Growth, Type And Application, Regions And Forecast To 2023

Given the wide-reaching effects of COVID-19 (Coronavirus) on Leukemia Therapeutics Market, companies are on the lookout for new opportunities to sustain in the coming years. Gain new insights into the market and alternative solutions for keeping production steady in unforeseen circumstances.

Leukemia Therapeutics Market Overview

Global leukemia therapeutics market is growing pervasively and will continue to do so in the years to come due to the growing prevalence of leukemia. With considerable advancements in biotechnology, various innovative therapies have emerged, which drive the market growth excellently. The proven efficacies of these therapeutics in providing effective treatment for leukemia are allowing the market to accrue exponentially on the global platform. Well-spread awareness about leukemia therapeutics has spurred the growth of the market.

Read news on: https://www.medgadget.com/2020/08/leukemia-therapeutics-market-to-grow-at-a-cagr-of-5-3-by-2023-covid-19-impact-analysis-top-comapnies-pfizer-inc-glaxosmithkline-plc-novartis-ag-bristol-myers-squibb-company-sanofi-s-a.html

Rising numbers of medical science and biotechnology companies is a major driving force behind the growth of the market. Besides, the improving outlook for leukemia treatments that are controlling the spread of the diseases fosters the market growth phenomenally. According to Market Research Future (MRFR), the global leukemia therapeutics market had valued at USD 10.7 BN in 2017. The valuation is further projected to appreciate at 5.3% CAGR during the assessment period (2018-2023).

The rapid adoption of leukemia therapeutics and increasing demand for effective treatment methods are driving the growth of the market. Additional factors, such as increasing numbers of R&D initiatives, clinical trials, and new approvals, are contributing to the growth of the market. Providers are collaborating with independent research centers and hospitals to bring novelties into therapies, which, as a result, are acting as major tailwinds for market growth.

On the other hand, high costs and lack of awareness are projected to impede the growth of the leukemia therapeutics market. Nevertheless, increasing numbers of drug discoveries would support market growth throughout the assessment period. Rapid uptake of these therapies by medical professionals, as well as patients and increasing success rates, are driving the market.

Leukemia Therapeutics Market Major Players:

Players leading the leukemia therapeutics market include Pfizer Inc. (US), Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Takeda Pharmaceutical Company Ltd (Japan), Amgen Inc (US), Hoffmann-La Roche AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), and Sanofi SA (France), among others.

Global Leukemia Therapeutics Market - Segments      

The market is segmented into three main dynamics to widen the scope of understanding,

By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.

By Application: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.

By Regions: Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.

These therapeutics are used to treat a range of leukemia types, including acute myelogenous, acute lymphocytic, chronic lymphocytic, chronic myelogenous, and others. Among these, acute lymphocytic leukemia (ALL) is the largest segment in the market. The prevalence of this type of leukemia is the major reason behind the growth of the segment. Additionally, rising numbers of clinical trials and regulatory approvals push the segment growth. For instance, recently FDA approved blinatumomab, a bispecific T-cell engager (BiTE), as an effective method to treat patients with acute lymphocytic leukemia.

Global Leukemia Therapeutics Market - Regional Analysis

North America dominates the global leukemia therapeutics market, heading with an increase in the prevalence of leukemia and the geriatric population. Besides, the presence of many well-established players, alongside innovative therapies is estimated to drive the leukemia therapeutics market in North America. The market growth is predominantly supported by the US market, which is growing due to the large patient pool and high healthcare expenditures.

Moreover, technological advancements and well-spread awareness about the availability of leukemia therapeutics, support market growth. The North American leukemia therapeutics market is projected to retain its dominance in the global market throughout the review period.

Europe stands second in the global leukemia therapeutics market. Increasing numbers of leukemia patients in the region drive the regional market predominantly. Furthermore, increased numbers of advanced treatment facilities, alongside the availability of skilled medical professionals and the government support for research & development, fosters regional market growth.

The Asia Pacific region is emerging as a promising market for leukemia therapeutics. Factors substantiating the market growth include increasing prevalence of leukemia and spreading awareness among people about the condition and availability of new treatment methods. China and India are proliferating markets for leukemia therapeutics, which contribute to the market growth in the region, majorly. The APAC leukemia therapeutics market is expected to grow phenomenally.

Global Leukemia Therapeutics Market   - Competitive Analysis

The leukemia therapeutics market appears fiercely competitive due to the presence of many well-established players. Significant investments are transpired in the field to bring innovations to the therapy and clinical trials. To gain a larger competitive share in the market, these players incorporate strategies such as partnerships, collaborations, mergers & acquisitions, expansions, and technology launch.  

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

Leukemia Therapeutics Industry/ Innovation/Related News:

March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS).

January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.

[affiliatetejas]

Antibody Drug Conjugates Market Size Forecast - 2026

To Gain More Insights into the Antibody Drug Conjugates Market, Browse Summary of the Research Report –

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug.  

https://www.coherentmarketinsights.com/ongoing-insight/antibody-drug-conjugates-market-181

By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.

In terms of marketing, three antibody drug conjugates have received regulatory approval.  The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.

“We Do Offer Sample of Antibody Drug Conjugates Market Report. Kindly go through the follow information in order to access sample copy.”

https://www.coherentmarketinsights.com/insight/request-sample/181

Table of Contents

https://www.coherentmarketinsights.com/ongoing-insight/toc/181

Top players in the market

Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc., Pfizer Inc., Sanofi, AbbVie Inc., Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.

Research methodology adopted by Coherent Market Insights

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

Primary Research (Trade Surveys and Experts Interviews)

Desk Research

Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Request A Sample Copy Antibody Drug Conjugates Market Report Click here:

https://www.coherentmarketinsights.com/insight/request-sample/181

Get PDF Research Report Brochure @

https://www.coherentmarketinsights.com/insight/request-pdf/181

Buy Now this Premium Report to Grow your Business @

https://www.coherentmarketinsights.com/insight/buy-now/181

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

Contact Us:

Name: Mr. Raj Shah

Email: sales@coherentmarketinsights.com

Phone: US +12067016702

Country: United States

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[abrreports-blog]

Hydroxyurea Market Key Trends, Drivers, Growth Opportunities, and 2025 Industry Chain Structure Analysis

The research study Hydroxyurea market 2020 launched by ABRReports.com provides the detailed analysis of current market status, investment plans, production and consumption, price trends, leading key companies, growth drivers and future prospect. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025

 Get the Sample Copy of Hydroxyurea market report at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-hydroxyurea-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report?form=request-report-sample

 The segmentation of Hydroxyurea study as mentioned below:

By Market Players:

Bristol-Myers Squibb, Euticals, Tecoland, Qilu Tianhe Pharmaceutical

 By Application

Chronic Myelogenous Leukemia, Myeloproliferative Disease, Sickle Cell Anemia, OtherOral, Intravenous

 The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc. The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2014 to 2019 and forecast data from 2020 to 2025.

 The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements. The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

 Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-hydroxyurea-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

 The key objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

 Purchase the research study @  https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-hydroxyurea-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report/checkout?option=one

 Key pointers of the Table of Contents:

Chapter 1 Industry Overview

Chapter 2 Major Segmentation (Classification, Application and etc.) Analysis

Chapter 3 Production Market Analysis

Chapter 4 Sales Market Analysis

Chapter 5 Consumption Market Analysis

Chapter 6 Production, Sales and Consumption Market Comparison Analysis

Chapter 7 Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 8 Marketing Channel Analysis

Chapter 9 Industry Chain Analysis

Chapter 10 Global and Regional Market Forecast

Chapter 11 Major Manufacturers Analysis

Chapter 12 New Project Investment Feasibility Analysis

Chapter 13 Conclusions

Continued…

 About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company which offers market research reports to individuals, organizations and industries to enhance and strengthen the decision making process. With associate thoroughgoing list of market research Publishers we tend to cut across over all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trend, information on products, regional market and keen business insights to our clients.

 Contact Us:

Scott Harris

Sales Manager

Email ID: sales@abrreports.com

Phone No.: +1-561-448-7424 

[martynnx-blog]

Antibody Drug Conjugates Market 2018 – Precise Outlook, Status & Forecast Till 2026

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug.  

By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.

Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market

In terms of marketing, three antibody drug conjugates have received regulatory approval.  The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.

Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market

Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/181

[thumbkenya76-blog]

AbbVie, Inc. (ABBV) Management Presents at Morgan Stanley 16th Annual Global Healthcare Conference (Transcript)

AbbVie, Inc. (NYSE:ABBV) Morgan Stanley 16th Annual Global Healthcare Conference September 12, 2018 11:40 AM ET

Executives

Bill Chase - Chief Financial Officer

Scott Brun - Head of AbbVie Ventures and VP of Scientific Affairs

Analysts

David Risinger - Morgan Stanley

David Risinger

Okay. So thanks everybody for joining us for the session with AbbVie. I just need to refer you to disclaimers at www.morganstanley.com/researchdisclosures. It’s very much my pleasure to welcome Bill Chase and Scott Brun. So Bill is the Company’s CFO. I’m sure many of you are familiar with him and he’s been in the position for several years and has overseen the Company’s execution of delivering results above expectations for the last several years. Scott is currently Head of AbbVie Ventures and Vice President of Scientific Affairs. He was previously the Head of Pharmaceutical Development and has been instrumental in advancing the Company’s pipeline. So it’s my pleasure to welcome them today. I guess I wanted to start off with a question regarding the execution against your plan.

So, clearly the Company has delivered better than expected performance over a number of years. Investors are skeptical about the longer term given the fear of the biosimilar threats to HUMIRA. So maybe you could sort of tackle it two ways. Talk about the financial targets for 2020 and your confidence in achieving those? And then maybe Scott, you could talk in a bit more detail about the pipeline and its ability to ultimately offset HUMIRA longer term?

Scott Brun

Sure. Well, so David thanks for having us. We always appreciate the opportunity to come out to the Morgan Stanley conference. I think as we start with the big picture and how we’re tracking relative to the long range guidance and particularly in light of that concern around what happens post 2022 when you have an LoE for HUMIRA in the U.S. Like the reality is, since even prior to the spin, this company has been preparing itself for what was going to be in an eventual LoE event around HUMIRA and that was known on day one and our strategy that we said internally and with the board was always trying to build the capabilities and the assets within the Company to be able to negotiate that events and remain a growth vehicle. And at that point in time, we said look our aspirations is to be top tier growth.

Now obviously there's two parts of that equation, one is, what is the HUMIRA curve look like and when, and you've seen us execute very nicely with our legal strategy and the settlements around the U.S. events to delay the onset of LoE in 2022, 2023 time period. The second piece though is what are you going to grow with? And that becomes essentially a pipeline question. And we always knew that we needed to have very, very good differentiated assets. We wanted to be a focus company. We wanted to focus primarily in the areas that we knew that play to our strengths.

So we focus primarily on immunology and oncology. And we set about building what we think is one of the most attractive late stage pipelines in the industry. And we can go through obviously in some detail and Scott's got a lot to say on that thing as well. But at the end of the day, what we called out last time, we updated the strategic plan, isn't if you take HUMIRA out of the mix and you benchmark us back to 2017, which is one of the plan was last updated. We had a business when we looked at our pipeline that we felt was -- we felt comfortable saying was going to grow from about $10 billion in sales size up to $35 billion in 2025.

And the way we're going to do that was through some best in category assets and then which Scott will share with you. Our strong franchise we built in HemOnc with IMBRUVICA and VENCLEXTA products like or at least that we are just underway launching and more recently launched like MAVYRET. And when we look at those assets and we look at the de-risk nature as well as the efficacy and safety that they've shown in a very broad clinical trial, we feel very comfortable that they can get into the market in their respective places and deliver upon those gross projections.

And so we remain very, very confident, pipeline is a huge part of the story. And if you look at our pipeline, not only do we have attractive assets, but this is a very diversified pipeline. We're not delivering all that grows just with one or two assets. There is 5, 6, 7 different aspects at play which we also think is fairly unique when we look at our peers.

David Risinger

Excellent. And maybe Scott, you could add a little bit on and since speak to investors pretty frequently which of the pipeline assets are potentially most underappreciated by investors as you discuss these biggest of pipeline contributors, longer term?

Scott Brun

No, absolutely, I didn't focus on that. Again, David thanks for having us. Bill hit on the number of important themes. When we launched AbbVie, now almost six years ago, focus was incredibly important to make sure that we had the right capabilities from discovery through commercialization market access in a few set areas where we really thought that we could differentiate ourselves with both internally discovered and developed assets as well as externally sourced opportunities. I think that’s been playing out extremely well. I mean I could take the rest of the time going through the qualities of the late-stage pipeline, but maybe I can hit on a few high points.

Certainly, in hematologic malignancies, when you look at it IMBRUVICA and VENCLEXTA, these are two first-in-class agents that are transforming hematologic malignancies of several types. I mean we look at IMBRUVICA the fact is in chronic lymphocytic leukemia, first and second line. It’s really becoming a mainstay of therapy. We've also seen significant results in Waldenstrom's macroglobulinemia. Most recently, we actually had a label update with a study looking in IMBRUVICA combination with Rituxan that again provides us a chemotherapy free option for this particular disease, opportunities in other malignancies like mantle cell lymphoma also tend to build the overall opportunity for IMBRUVICA.

We’re going to continue to progress IMBRUVICA particularly in first line CLL where we think there’s a lot of opportunities in particular in combination with VENCLEXTA first-in-class Bcl-2 inhibitor which have a Phase 2 study captivate to demonstrate the combination of IMBRUVICA and VENCLEXTA can drive to minimal residual disease, essentially no detectable disease by advanced diagnostic methods in 70% to 80% of patients. And so this could really transform the care of CLL away from toxic chemotherapies to a drug combination that could put patients into long-term remission with much less tolerability baggage.

Now talking a little bit more about VENCLEXTA beyond these opportunities in CLL, we’re currently under regulatory review in acute myelogenous leukemia. This is a very devastating rapidly progressive disease that we’ve demonstrated that VENCLEXTA added on to standard-of-care in first line patients who can’t tolerate the harshest chemotherapy can double or triple complete response rates, which led to a breakthrough therapy designation from FDA.

And as I said, current regulatory review that could lead to an approval next year, VENCLEXTA a lot of opportunity in multiple myeloma where we are currently in Phase 3 looking at in combination with Velcade and dexamethasone in second line plus multiple myeloma. We also think there are opportunities in first line myeloma and certain genetically defined population, so a tremendous opportunity is there.

Moving on to our immunology franchise, risankizumab, the partnered assay with BI and anti-IL-23 that has demonstrated some of the highest responses that we’ve seen in patients with psoriasis PASI 100 scores, complete skin clearance on the order of 50% to 60% Superiority versus STELARA, HUMIRA the ability to treat patients who have failed prior TNF inhibitors in a quarterly dosing pattern. And so, risa is currently under regulatory review as well.

Our selective JAK1 inhibitor, upadacitinib, for which we disclosed 5 trials in rheumatoid arthritis. We studied this drug in first line therapy patients who are naive to any treatment, all the way through patients who have failed prior TNF inhibitors. We've lifted Upa with and without methotrexate. We've demonstrated Superiority to HUMIRA. We have over 4,000 patients worth of data. And then every one of these contexts, Upa is performing at the top of the class, certainly directionally, although we have no head-to-head studies directionally better than what we see with baricitinib vs tofacitinib.

I think we've shown from the safety perspective that our rates for venous thromboembolism which has become a point of discussion with this class, really do not differ from placebo and our randomized controlled trials, nor do they worsen overtime, nor do they demonstrate any type of dose response. Certainly, if we want to get into a little bit more of the recent competitive context with recent risa and upa, David during the question we can do that.

ORILISSA, otherwise known as elagolix, the first new therapy for endometriosis related pain in a long time. This disease affects millions of women. They are unsuccessfully treated with combination of oral contraceptives or opioid pain management. We've demonstrated that with this oral therapy that affects the GnRH axis. We can lead to high levels of pain control and do it with a much improved side effect profile relative to show within the nuclear option Lupron.

So, we're in the launch phase of this drug right now. We're in Phase 3 in analysis of bleeding related to uterine fibroid. Another very common gynecological condition where again our two Phase 3 studies that have read out have demonstrated very high levels of efficacy, 75% or so significance of patients had significant reduction in their bleeding.

Again, I could keep going on and on. But I think the point here is as Bill said, diversified assets across a variety of different therapeutic areas that actually have potential beyond these initial indications that I've laid out. And I think as you seen with HUMIRA one of our themes is, to really understand biology and take it to places that it may not have been studied before.

David Risinger

Great. We could just follow up on the competitive landscape…

Scott Brun

We do a couple of announcements over the past year, so…

David Risinger

Yes, could you touch on those?

Scott Brun

Certainly, why don't we go ahead and start with the theme to data and what, I've always got to be careful about talking about someone else who is single study. To sum up what I'll say is based on what we saw from the Phase 2 data in the public domain, I took a Phase 3 data from this first trial or are consistent with that data set?

On the efficacy side both filgotinib and upadacitinib, as I said before directionally appear to provide the potential for improved efficacy relative to baricitinib or tofacitinib. We got to be a careful about our cross-study comparisons here of course especially since we don't know the baseline characteristics of the filgotinib population in total. I would say if you look at the ACR scores, there is puts and takes looking between upa and filgotinib. If you look at some of the DAS scores, which are a high stringent measure of disease control, low disease activity and clinical remission, I can certainly say that, again, all the caveats across study comparisons taking into account that for low dose of upadacitinib is performing every bit as well, if not maybe directionally better than what we see with filgotinib.

So, not seeing clear points of differentiation on the efficacy side, safety is harder to compare because we've got different bits and pieces of what's been shared. I'm glad no patients have venous thromboembolism on the filgotinib trial. But as we know, even patients on background therapy can see VTE. So I think before we can say exactly what that means, we need to see their whole program it's in context. And certainly, we've shared some information on infections, last year so on. I think at this point, it's too early to say that there is any kind of clear signal what differentiation on these low incidence events.

The one thing I do want to point out is that we will be filing an RA with upadacitinib before the end of this year, actually one of the things I must point out, before the end of this year, again, I don't know if Gilead had spoken to their timing when they were just in here. As I understand, the critical path for them is to complete the man-to-male reproductive study to de-risk the 200 milligram dose to see exactly what the benefit risk on that dose is. As I understand that that may put them more than a year behind our current filing timeline.

David Risinger

Got it. That's very helpful. Maybe we could pivot and Bill, you could talk about potential changes in U.S. drug pricing. Obviously, we have to wait and see. And if you could also touch on the notion of rebates going away, it sounds like a pretty big statement. And we'll still need to learn more on what the next steps are from HSS. But it'd be helpful for you to just frame it as you see it currently. And then touch on the rebate issue. Rick had spent a fair amount of time on the 2Q call. So one can refer to that transcript for lots of detail, but still be helpful because it's topic on investors' mind?

Bill Chase

Sure. So look, pricing has been a focus for the industry for the last several years. And it's clear that the administration has made it a focus in these years as well. So we historically whatever we do on our long range plan in the U.S. while we continue to believe the U.S. will remain a price positive environment. We always prudently scale back the rates of increases. So from a long range plan perspective, we've always kind of forecasted because it’s wise to forecast that way that the pricing environment will be getting a little tougher. But beyond the forecast, you've seen actions throughout the industry that have shown the dialogue around price is beginning to have an effect.

So for example, most companies now have moved to one price increase per year. We made a statement couple of years ago that we were doing that. And likewise, price increase is tend to be single digit. We have a statement similar to that as well. And so I think that you are beginning to see an impact through the industry a change in pricing behaviors. And of course, the fall through of those price increases are never in line with list. So I think if you really look at the data right now, you could say on a net-net basis while pricing is still positive in the U.S., it’s probably single-digit fall through, low-single-digit fall through maybe close to medium. But I would say try more like low-single-digits. So it’s clearly having an impact on the industry.

Now, we’re fortunate, we -- our growth is being driven by volume, not by price. If you look at our growth rates this year, they’ve been quite stunning on the top line. Probably last quarter, we had 17% operational growth, I think price overall was about 1% of that. So, when you have new products that are differentiated and you’ve got areas of high unmet need, you can drive impressive top and bottom line performance via volume and that’s what we’ve been doing.

Now, where pricing is going to go from here, little tough to call and obviously we got an initial look at the ideas in the blueprint. But while it was very comprehensive and had some truly creative ideas and we still need to see the details. And so we’re waiting along with the rest of the industry. We haven’t seen major changes to the contracting process to date, because of that. I think it’s kind of, we’re waiting and seeing. Although my guess is, our basic assumption and our long range plan is accurate and pricing will continue to moderate in this market.

In terms of the structural discussion around rebates and the questions that we would need to sort out, I think there’s two really that come to mind. First and foremost is how big, if we move into a paradigm where rebate contracting moves away, right. We move to some other type of contracting. The question is how big of a population of contracts are impacted. The Safe Harbor Provisions directly refers to government business, and the type of contract and that relies on PBM with the government is Medicare. If you look at AbbVie’s U.S. mix about 15% of our business was Medicare.

So, if it just stays within that area, you got 85% of the business in the U.S., which is not impacted. So we need to sort that out and I know some people feel that, it will rapidly move to commercial. We’re not sure, we have to see, how that plays out. That’s an important assumption. But maybe even more important is what rebate contracts are replaced with. We absolutely believe that the government and the market as not going to move away from a scenario, where you can give volume based contracts. It’s kind of a cornerstone of this industry, right. You give contracts based on based on patients under plan, the patient lives under plan and also the ability of that plan to drive compliance via formulary.

And those two things basically add up to a volume based contract. As long as volume based contracting is permitted, we don’t see any reason to believe that it wouldn’t be. It doesn’t really impact our business model. Now, we may need to figure out how you move from a rebate contract to a discount contract. But that’s just, that’s a contract form, it wouldn’t change the overall strategy. So yes, I understand why there’s a lot of concern around this change. But at the end of the day, I think it has less impact on manufacturers then perhaps the PBMs.

David Risinger

That’s extremely helpful. Let me pause there and see if there are any questions before I continue.

Question-and-Answer Session

Q - David Risinger

Okay. So one of the other topics that came up earlier in the year was the co-pay accumulator programs on the part of payers, and obviously, that has some marginal negative impact on reported sales. But could you just recap that and talk about how much of an inflection might be if more payers adopt such accumulators in 2019?

Bill Chase

Yes, sure. So, what we saw play out in the first quarter of 2018 was that there was a significant portion of patients that found themselves on high deductible plans with a co-pay accumulator. That number was roughly 4% to 5% of our commercial business which is about 80%. I'm talking to HUMIRA for example, okay. So if not necessarily not the lion's share, but it's a meaningful portion of patients.

And with this co-pay accumulator, especially did this concept was it ultimately ensured that the patient was on the hook for the full deductible even in the event that the manufacturer was willing to extend a co-pay card. Now, we fundamentally believe one of the issues in healthcare industry is co-pays that patients are burdened with. And so in most cases where we're able to, we offer co-pay assistance in order to alleviate that burden and that out of pocket burden on the consumer, the patient. We think that's absolutely the right thing to do.

What was somewhat perverse about the co-pay accumulators is it essentially could block our ability to do that. And so our view is, it is absolutely a poor contract form. And furthermore, we believe that a lot of people that were in co-pay accumulators may not clearly in plans that had co-pay accumulator, may not clearly understand what the ramifications for those plans were. And we're going to get surprise in the second quarter when they found out that their co-pay assistance have the limited a fixed amount and they now had to pay the deductible. And these deductible could be anywhere at $3,000 or $4,000. So a meaningful hit to your average patient, which in normal course would be covered by co-pay assistance and would not be taxing the patient out of pocket.

So, they get absolutely a horrific insurance form for the patient, it's actually rations their ability to get medications they need. And frankly the medications that we're selling, whether it be HUMIRA or anything else that we've got in our portfolio, these are for life threatening illnesses. And so to basically to private patients of access to that, that therapeutic, based on their ability to pay out of pocket, that was just absolutely the wrong thing to do.

So we recognize that this issue existed, we recognize that a lot of patients might be surprised. It was going to play out in Q2 and Q3 because really frankly, they had to burn through their co-pay cards before they discovered that they're still on the hook for the deductible. And in our Q1 call, we did adjust our HUMIRA guidance number down slightly to account for additional co-pay assistance that we would be able to provide these patients until we were able to sort themselves through this situation.

So, it came up as an issue on our first quarter comp. What I can tell you is it's largely tracking in line with what our expectations were. I think that the measures we've taken have largely been effective. There's been a lot of patient education by patient groups over the nature of these programs. So I like to think that we have wiser patients that will, if to the extent that they can avoid these sorts of insurance constructs in 2019, we certainly think there'll be inclined to do so.

And right now as we forecast '19, we don't see this patient population or the patient population that subject to this form of insurance coverage as expanding dramatically. We think it will largely be contained in a number roughly the size that we're seeing in '18.

David Risinger

Okay that's very helpful. And Scott, maybe we could pivot to IMBRUVICA. So there is an interesting Phase 3 trial in pancreatic cancer that's supporting out soon. Could you just frame that for us?

Scott Brun

Yes, absolutely. David, I mean, again it's better to go back and remind you all the overall strategy when we proceeded with the Pharmacyclics deal. So we felt that, look the foundation of this asset was going to be in the type of hematologic malignancies that I have spoken to particularly CLL. As you progress beyond there, we have increasing levels of risk adjustment that's spoken about some of the other malignancies where we seen great promise. PHOENIX in first line diffuse large B-cell lymphoma didn't measure up the expectations. That's a discrete duration of therapy against difficult effective standard of care, R-CHOP.

But again because of those considerations even the fact that we don't successful there, didn't mitigate our overall expectations for the assay. I would put pancreatic cancer in even another lower bucket with regard to the probability of success that we would apply to that. Obviously, this is a devastating condition for which there exist few good options. And so, we have a Phase 3 trial that is looking at IMBRUVICA added on to paclitaxel gemcitabine. That should be reading out before the end of the year, but again, this is high hurdle, haven't seen the data yet. But certainly, we don't have appropriate expectations for that.

Some of the other trials on IMBRUVICA that will be reading out, well certainly, we talked about CLL and again the iLLUMINATE trial which what's at IMBRUVICA plus GAZYVA versus chlorambucil GAZYVA to continue to enhance our body of data in first line CLL. We top line that and I think maybe able to say more on that at ASH. And then we've got ongoing study that we'll be reading out more in the 2019-2020 timeframe and things like follicular lymphoma first line mantle cell in particular.

David Risinger

Excellent. Well, I think we are out of time. I think we can go on the lot longer, but unfortunately we're out of time. So thank you so much for joining us. Appreciate that.

Source: https://seekingalpha.com/article/4205875-abbvie-inc-abbv-management-presents-morgan-stanley-16th-annual-global-healthcare-conference?source=feed_all_articles

[techsciresearch]

Chemotherapy Segment to Dominate Leukemia Therapeutics Market During Forecast Period

Increasing incidences of cancer cases around the globe to drive the growth of global leukemia therapeutics market

According to TechSci Research report, “Global Leukemia Therapeutics Market By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Others), By Severity (Acute, Chronic), By Blood Cell (Lymphocytic, Myelogenous), By Age Groups (0-15, 15-30, 30-50, 50+), By Sex (Male, Female),      By Treatment (Targeted Therapy, Interferon Therapy, Radiation Therapy, Surgery, Stem Cell Transplantation, Drugs, Gene Therapy, Others), By Diagnosis (Blood test, Biopsy, Physical Exam, Imagining), By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal), By Drugs (Antimetabolites, Biosimilars, & Others), By Region, Forecast & Opportunities, 2025”, the global leukemia therapeutics market is expected to grow at a formidable rate during the forecast period on account of the increasing prevalence of leukemia. Additionally, drastic increase in the mortality rate due to leukemia is further expected to propel the market during forecast period. Furthermore, strong developing pipeline, increasing approvals of novel & innovative drugs and immunotherapies are projected to spur the market during forecast years. Moreover, technological advancements & innovations and faster approvals by the regulatory agencies are further creating lucrative opportunities for the market. However, lack of awareness among the population pertaining to the disease and its severity can hamper the growth of market during forecast period. Additionally, presence of generic drugs and limited availability of treatment options restrict the growth of market over 2025. Furthermore, lack of early diagnosis of the disease also obstruct the market growth over the next few years. Moreover, the high cost of treatments and associated adverse effects are further slowing down the growth of market.

 Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on" Global Leukemia Therapeutics Market"

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

The global leukemia therapeutics market is segmented based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and region. Based on blood cell, the market can be divided into lymphocytic and myelogenous. The myelogenous segment is expected to dominate the market on account of the large number of treatment options available for the treatment of chronic myeloid leukemia and high incidence rate of chronic myeloid leukemia. Based on age groups, the market can be segmented into 0-15, 15-30, 30-50 and 50+. The 30-50 years age group segment is expected to dominate the market since leukemia mostly affects the middle age population. The 15-30 age group segment is expected to witness growth on account of the drastic increase in the number of patients of this age group suffering from leukemia. Based on sex, the market can be bifurcated into male and female. The male segment dominates the market since male population especially in their middle age are affected by this disease. Leukemia is often regarded as the most common type of cancer in males. Based on treatment, the market can be categorized into targeted therapy, interferon therapy, radiation therapy, surgery, stem cell transplantation, drugs, gene therapy, immunotherapy, vaccine therapy, chemotherapy and blood transfusion. The chemotherapy segment is expected to dominate the market during forecast period owing to an ability to kill cancerous cells or inhibiting its proliferation and maintain a normal level of lymphocytes. Additionally, increased survival rate of the patients treated with chemotherapy is again fueling the demand for the segment. The targeted therapy segment is expected to register the highest growth during the forecast period. This can be ascribed to the fewer side effects and higher efficacy. Additionally, targeted therapy has a higher success rate as compared to the other treatment options available.

Novartis, AbbVie, Bristol-Myers Squibb, Roche, Amgen, Gilead sciences, Celgene, Eisai, AstraZeneca, Incyte Corporation, Johnson & Johnson, Biogen, Merck, PerkinElmer, Eli Lilly, Abbott, Sumitomo Dainippon Pharma, Thermo Fisher Scientific, Otsuka Holdings, Astellas Pharma and others are some of the leading players operating in global leukemia therapeutics market. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, In May 2018, Novartis launched its CAR-T cell therapy for the second indication treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma. With the innovative launch of Kymriah, Novartis is now a pioneer of leukemia immunotherapies.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4534

Customers can also request for 10% free customization on this report.

“Asia-Pacific is expected to witness the highest growth in the leukemia therapeutics market during the forecast period on account of the increasing investments in research and development for the treatment of leukemia and the growing prevalence of leukemia in countries such as Japan and India. Additionally, the increasing disposable income of consumers and improving healthcare infrastructure in the region is further expected to propel the market during forecast period. Also, growing focus of market players on addressing healthcare based demands in these countries is further expected to foster the growth of market through 2025.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Leukemia Therapeutics Market By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Others), By Severity (Acute, Chronic), By Blood Cell (Lymphocytic, Myelogenous), By Age Groups (0-15, 15-30, 30-50, 50+), By Sex (Male, Female),      By Treatment (Targeted Therapy, Interferon Therapy, Radiation Therapy, Surgery, Stem Cell Transplantation, Drugs, Gene Therapy, Others), By Diagnosis (Blood test, Biopsy, Physical Exam, Imagining), By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal), By Drugs (Antimetabolites, Biosimilars, & Others), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of global leukemia therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global leukemia therapeutics market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com